Shero Imaging First Missouri Clinic to Offer IceCure ProSense Cryoablation
IceCure Medical’s ProSense system, recently FDA-authorized for low-risk breast cancer, was installed at Shero Imaging in St. Louis, making it Missouri’s first clinic to offer breast cryoablation. Procedures will be conducted by board-certified radiologist Dr. Tish Singer using minimally invasive tumor-freezing technology.
1. Installation at Shero Imaging in St. Louis
IceCure Medical completed the sale and installation of its ProSense cryoablation system at Shero Imaging’s St. Louis facility, marking the first use of this technology in Missouri. Shero Imaging’s founder and board-certified radiologist, Dr. Tish Singer, will oversee breast cancer cryoablation procedures using the system.
2. FDA Authorization and Clinical Impact
ProSense® is the only liquid-nitrogen-based cryoablation system granted FDA marketing authorization for treating low-risk breast cancer in women aged 70 and above who cannot undergo surgery. The technology freezes tumors in office-based settings, accelerating recovery, reducing pain and lowering surgical risks.
3. Growth Strategy and Market Potential
This regional adoption supports IceCure’s expansion strategy to drive clinic partnerships across the U.S. Inclusion in proposed medical guidelines for cryoablation could boost unit sales and enhance the company’s presence in the minimally invasive oncology market.